source
- Vaxcyte’s pneumococcal vaccine meets primary goals in Phase 3 trial, challenging Pfizer and MerckVaxcyte announced that its experimental pneumococcal vaccine, VAX-31, achieved the primary endpoints in a pivotal Phase 3 study. The data, presented in a company release, show the shot met its pred…
- Vaxcyte's experimental pneumococcal vaccine meets primary endpoints in Phase 3 trialVaxcyte announced that its experimental pneumococcal vaccine, VAX-31, achieved the primary endpoints in a Phase 3 trial. The study enrolled just over 3,500 adults aged 50 and older who were random…